Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 3,104 Shares

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 3,104 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $134,123.84. Following the completion of the sale, the insider now directly owns 75,289 shares of the company's stock, valued at approximately $3,253,237.69. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Dennis Cho also recently made the following trade(s):

• On Friday, September 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total value of $10,983.96.
• On Monday, August 5th, Dennis Cho sold 709 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37.

Twist Bioscience Stock Up 1.3 %

Shares of Twist Bioscience stock traded up $0.55 during trading hours on Friday, reaching $43.34. 341,909 shares of the company were exchanged, compared to its average volume of 783,825. The stock's fifty day moving average is $45.23 and its 200 day moving average is $43.56. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The company had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. During the same period in the prior year, the business earned ($1.01) EPS. Twist Bioscience's revenue for the quarter was up 27.7% on a year-over-year basis. As a group, equities analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TWST. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience in the 2nd quarter valued at $43,000. Blue Trust Inc. increased its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after buying an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience in the second quarter valued at $61,000. Nisa Investment Advisors LLC lifted its holdings in Twist Bioscience by 31.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company's stock worth $113,000 after buying an additional 546 shares during the last quarter. Finally, CWM LLC boosted its position in shares of Twist Bioscience by 27.4% during the 2nd quarter. CWM LLC now owns 2,437 shares of the company's stock worth $120,000 after acquiring an additional 524 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Evercore ISI increased their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday. TD Cowen upped their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a "buy" rating in a report on Thursday, June 13th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an "outperform" rating in a research report on Monday, August 5th. The Goldman Sachs Group boosted their target price on Twist Bioscience from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, July 9th. Finally, Barclays lowered their price target on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and an average target price of $51.63.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.